2. Signaling Pathways
  3. GPCR/G Protein
  4. Platelet-activating Factor Receptor (PAFR)
  5. Platelet-activating Factor Receptor (PAFR) Inhibitor

Platelet-activating Factor Receptor (PAFR) Inhibitor

Platelet-activating Factor Receptor (PAFR) Inhibitors (12):

Cat. No. Product Name Effect Purity
  • HY-112825
    TSI-01
    		Inhibitor 98.31%
    TSI-01 is a pro-inflammatory phospholipid mediator that is rapidly synthesized by lyso-PAF acetyltransferase (lyso-PAFAT) in response to extracellular stimuli. Two types of lyso-PAFAT have been identified: lysophosphatidylcholine acyltransferase (LPCAT)1, which is mostly expressed in the lungs, and LPCAT2, which is expressed in inflammatory cells. TSI-01 is a selective inhibitor of LPCAT2 (IC50s=0.47 versus 3.02 μM for human LPCAT2 and LPCAT1, respectively). 60 μM it is shown to suppress PAF biosynthesis in mouse peritoneal macrophages stimulated with a calcium ionophore.
  • HY-N1717
    2-Acetylbenzoic acid
    		Inhibitor
    2-Acetylbenzoic acid, a Benzoic acid (HY-N0216) derivative, is a weak platelet aggregation inhibitor. 2-Acetylbenzoic acid inhibits Adenosine 5'-diphosphate (ADP, HY-W010918)-induced platelet aggregation.
  • HY-P2606
    Antiflammin 2
    		Inhibitor 99.50%
    Antiflammin 2 inhibits the synthesis of platelet-activating factor (PAF) with the IC50 of 100 nM.
  • HY-N3643
    Cryptomeridiol
    		Inhibitor
    Cryptomeridiol is a platelet-activating factor (PAF) receptor binding inhibitor. Cryptomeridiol has melanogenesis inhibitory activity in the α-MSH (HY-P0252)-stimulated B16 melanoma cells.
  • HY-123367
    Rubraxanthone
    		Inhibitor
    Rubraxanthone is a compound with multiple biological activities. Its pharmacokinetic parameters were determined in mice and it showed a certain concentration variation pattern in plasma after oral administration.
  • HY-117811
    (R,R)-MK 287
    		Inhibitor
    (R,R)-MK 287 (L-680574) is a tetrahydrofuran derivative that potently inhibits the binding of [3H]C18-PAF to human platelets, polymorphonuclear leukocytes (PMNs), and lung membranes with Ki values???of 6.1, 3.2, and 5.49 nM, respectively. (R,R)-MK 287 potently and selectively inhibits PAF-induced platelet aggregation (ED50=56 nM) and elastase release from PMNs (ED50=4.4 nM). (R,R)-MK 287 inhibits PAF-induced lethality in mice (ED50=0.8 mg/kg, po) and PAF-induced bronchospasm in guinea pigs (ED50=0.18 mg/kg).
  • HY-N9300
    1,6-Dihydro-4,7-epoxy-1-methoxy-3,4-methylenedioxy-6-oxo-3,8-lignan
    		Inhibitor
    1,6-Dihydro-4,7-epoxy-1-methoxy-3,4-methylenedioxy-6-oxo-3,8-lignan, a lignan derivative from the ethyl acetate soluble fraction of twigs of Magnolia denudate (Magnoliaceae), exhibits anti-platelet-activating factor (PAF) activity. PAF is a potent lipid mediator in inflammation and asthma.
  • HY-118779
    Rhazimine
    		Inhibitor
    Rhazimine is an indole alkaloid that is a dual inhibitor of arachidonic acid metabolism and platelet activating factor-induced platelet aggregation.
  • HY-N1620
    1-Cinnamoylpyrrolidine
    		Inhibitor
    1-Cinnamoylpyrrolidine (Compound 3), a crude extract prepared from Piper caninum, is a DNA strand scission agent, induces the relaxation of supercoiled pBR322 plasmid DNA. 1-Cinnamoylpyrrolidine (Compound 4) inhibits platelet aggregation induced by PAF with an IC50 of 37.3 μM.
  • HY-106062
    CV 3988
    		Inhibitor
    CV 3988 is a specific inhibitor of platelet-activating factor (PAF).
  • HY-N11932
    Piperulin A
    		Inhibitor
    Piperulin A is a potent inhibitor of PAFR. Piperulin A inhibits the specific binding of PAFR on isolated rabbit platelet plasma membranes with an IC50 of 7.3 μM.
  • HY-N3054
    Pinusolidic acid
    		Inhibitor
    Pinusolidic acid is a platelet-activating factor (PAF) inhibitor with an IC50 of 23 μM.